Tacrolimus-related hypertrophic cardiomyopathy in an adult cardiac transplant patient

Chinese Medical Journal

Volumn 125, Issue 7, 2012, Pages 1352-1354

  Liu, Tong ^a   Gao, Yun ^a   Gao, Yu Long ^a   Cheng, Yu Tong ^a   Wang, Su ^a   Li, Zhi Zhong ^a   Zhang, Hai Bo ^a   Meng, Xu ^a   Ma, Chang Sheng ^a   Dong, Jian Zeng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cardiac transplantation; Left ventricular hypertrophy; Sirolimus; Tacrolimus

Indexed keywords

RAPAMYCIN; TACROLIMUS;

ADULT; ANOREXIA; ARTICLE; BLOATING; CARDIAC GRAFT REJECTION; CASE REPORT; CONGESTIVE HEART FAILURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HEART CATHETERIZATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; MALE; REMISSION; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; TACROLIMUS;

EID: 84859968726     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.07.030     Document Type: Article

References (17)

1. European FK506 Multicenter Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994; 344: 423-428.
2. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997; 64: 436-443.
3. Abu-Elmagd K, Fund JJ, Reyes J, Casavilla A, Van Thiel DH, Iwaki Y, et al. Management of intestinal transplantation in humans. Transplant Proc 1992; 24: 1243-1244.
4. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6: 1377-1386.
5. Noto S, Fujiwara H, Ban T, Ohara K. Cardiotoxicity of long-term intravenous administration of FK506 in rabbits: dose relationship and recovery after discontinuance. Transplant Proc 1994; 26: 855-857.
6. Atkison P, Joubert G, Barron A. Hypertrophic cardiomyopathy associated with tacrolimus in pediatric transplant patients. Lancet 1995; 345: 894-896.
7. Turska-kmiec A, Jankowska I, Pawlowska J, Kalicinski P, Kawalec P, Tomyn M, et al. Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient. Pediatr Transplant 2007; 11: 319-323.
8. Jarzembowski TM, John E, Panaro F, Manzelli A, Cabrera A, Greco A, et al. Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6-year-old recipient. Pediatr Transplant 2005; 9: 117-121.
9. Pappas PA, Weppler D, Pinna AD, Rusconi P, Thompson JF, Jaffe JS, et al. Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy. Pediatr Transplant 2000; 4: 45-49.
10. Coley KC, Verrico MM, McNamara DM, Park SC, Cressman MD, Branch RA. Lack of tacrolimus-induced cardiomyopathy. Ann Pharmacother 2001; 35: 985-989.
11. Yoshihiko S, Masatsugu H, Takao S. Multicenter prospective investigation on cardiovascular adverse effects of tacrolimus in kidney transplantations. Cardiovasc Drug Ther 2003; 17: 141-149.
12. Jayaraman T, Brillantes AM, Timerman AP, Fleischer S, Erdjument-Bromage H, Tempst P, et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Bio Chem 1992; 267: 9474-9477.
13. Lam E, Martin MM, Timerman AP, Sabers C, Fleischer S, Lukas T, et al. A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor. J Biol Chem 1995; 270: 26511-26522.
14. Atkinson PR, Joubert GI, Guiraudon C, Armstrong R, Wall W, Asfar S, et al. Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. Transplantation 1997; 64: 773-775.
15. Nakata Y, Yoshibayashi M, Yonemura T, Uemoto S, Inomata Y, Tanaka K, et al. Tacrolimus and myocardial hypertrophy. Transplantation 2000; 69: 1960-1962.
16. Kushwaha SS, Raichlin E, Sheinin Y, Kremers WK, Chandrasekaran K, Brunn GJ, et al. Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. Eur Heart J 2008; 29: 2742-2950.
17. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618.